Search

Displaying results 3291 - 3300 of 10000 in total
  1. Drug

    Naratriptan

    go.drugbank.com/drugs/DB00952
    Approved

    Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.

    Synonyms: N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide, N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
  2. Drug

    Argatroban

    go.drugbank.com/drugs/DB00278
    ApprovedInvestigational

    Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. … The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary

  3. Drug

    Procarbazine

    go.drugbank.com/drugs/DB01168
    ApprovedInvestigational

    An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.

    Synonyms: N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine, N-Isopropyl-α-(2-methylhydrazino)-p-toluamide
  4. Drug

    Plazomicin

    go.drugbank.com/drugs/DB12615
    Approved

    On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. … It is marketed as Zemdri and is administered via once-daily intravenous infusion.

  5. Drug

    Brivaracetam

    go.drugbank.com/drugs/DB05541
    ApprovedInvestigational

    Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. … It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760].

  6. Drug

    Triheptanoin

    go.drugbank.com/drugs/DB11677
    ApprovedInvestigational

    [A214812,A214817] Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin. … [L14612] In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly

  7. Drug

    Clobetasol propionate

    go.drugbank.com/drugs/DB01013
    ApprovedInvestigational

    [L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974. … Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors.

  8. Drug

    Levomethadone

    go.drugbank.com/drugs/DB13515
    Investigational

    Categories: Drugs Used in Opioid Dependence, Drugs Used in Addictive Disorders
  9. Drug

    N-(2-Aminoethyl)-1-aziridineethanamine

    go.drugbank.com/drugs/DB15643
    Experimental

    First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease

    Synonyms: N-(2-((2-Aminoethyl)amino)ethyl)aziridine, N-(2-aminoethyl)-1 aziridine-ethanamineCategories: Agents Acting on the Renin-Angiotensin System
  10. Drug

    Paramethadione

    go.drugbank.com/drugs/DB00617
    Approved

    Paramethadione is an anticonvulsant in the oxazolidinedione class. It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.